Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of AIN457 in psoriatic arthritis
2009-011622-34Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Primary endpoints: Safety and tolerability of AIN457 and Immunogenicity of AIN457. Started Jan 2010; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2009-011622-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011622-34.